System and method for predicting polycystic ovarian morphology (PCOM)
Through a mass spectrometry detection system, combining classical and 11 oxygen and androgen indicators, a prediction model of polycystic changes in ovarians was established, which solved the shortcomings of detection methods in the existing diagnosis, improved prediction accuracy and diagnostic support, and for PCOS The diagnosis of subtypes provides better tools.
Patent Information
- Application Number
- PCT/CN2023/094176
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-09
- Filing Date
- 2023-05-15
- Publication Date
- 2024-11-14
AI Technical Summary
In the existing diagnosis of polycystic ovarian syndrome (PCOS), especially the evaluation of ovarian polycystic alteration (PCOM), there is insufficient sensitivity and accuracy of the detection method of high androgen hormones, and due to pathophysiological heterogeneity, it is difficult to fully understand the cause. , affects subtype diagnosis and treatment.
A mass spectrometry (MS)-based detection method was developed to simultaneously detect classical androgen and 11 oxygen and androgen series indicators, and a system and method for predicting polycystic changes in the ovarian region were established, combining testosterone and 11-ketoandrothenide di The probability of ovarian polycystic changes in the subjects were calculated by formulas and grouped risk assessment was performed.
Improve the prediction accuracy of ovarian polycystic changes, provide more comprehensive and accurate diagnostic tools, help understand the etiology of PCOS, and provide support for subtype diagnosis, improving treatment strategies for polycystic ovarian syndrome.
Smart Images

Figure PCTCN2023094176-FTAPPB-I100001 
Figure PCTCN2023094176-FTAPPB-I100002 
Figure PCTCN2023094176-FTAPPB-I100003
Abstract
Description
System and method for predicting polycystic ovarian changes (PCOM) Technical Field
[0001] The present application relates to a system and method for assessing the probability of polycystic ovary (PCOM) in a subject. Background Art
[0002] Polycystic ovary syndrome (PCOS) is a reproductive and metabolic disease that is the most common cause of anovulatory infertility, with an incidence of 5-20% in women of childbearing age. In the absence of other specific diagnoses, adults are diagnosed with at least two of three characteristics: excessive androgen production, ovulatory disorders (prolonged menstrual cycles and amenorrhea are its main manifestations), and polycystic ovarian changes (PCOM). Therefore, women with PCOS are divided into four phenotypic groups based on a random combination of signs and symptoms. Most affected women also have other metabolic dysfunctions, such as obesity and insulin resistance. Mainly due to the heterogeneity of the phenotype, the pathophysiology of PCOS remains unexplained, and clarifying the causes and subtype diagnosis of different PCOS phenotypes is very necessary for subsequent treatment. The present invention attempts to explore the cause of PCOM through modeling and provide tools for subtype diagnosis.
[0003] Hyperandrogenism is considered a potential driver of PCOS. Some studies suggest that elevated androgen levels during adolescence can be an early sign of PCOS. Furthermore, genetic aberrations in the androgen receptor have been found in women with PCOS, increasing circulating androgens and leading to abnormal folliculogenesis. There is also strong evidence that excessive exposure to androgens in utero contributes to the development of PCOS in adulthood.
[0004] Despite these population-based findings and basic research, however, hyperandrogenism cannot be observed in all phenotypic groups of PCOS in clinical practice. To explore the role of hyperandrogenism in PCOS, two issues need to be clarified: (1) Due to the phenotypic heterogeneity of PCOS, hyperandrogenism may be the main cause of some characteristics but not others. Therefore, evaluating the contribution of hyperandrogenism in PCOS may provide another perspective for understanding the etiology of PCOS. (2) In clinical practice, only typical androgens, mainly testosterone (T), are routinely tested when diagnosing PCOS. In addition, the widely used measurement method, chemiluminescence immunoassay, has problems with insufficient sensitivity and accuracy for circulating androgen levels in women. Currently, mass spectrometry (MS)-based detection methods are internationally recognized as the gold standard for steroid (including androgen) detection.
[0005] A group of nonclassical androgens, namely adrenal-derived 11oxy androgens (11oxyC19), have recently been implicated as potentially involved in PCOS. 11β-Hydroxyandrostenedione (11OHA4) is the most abundant 11oxyC19 androgen, while 11β-hydroxytestosterone (11OHT) is primarily produced in the adrenal glands. These metabolites are primarily converted to 11-ketoandrostenedione (11KA4), 11-ketotestosterone (11KT), and 11-keto-5α-dihydrotestosterone (11KDHT) in peripheral tissues. Evidence suggests that 11KT and 11KDHT are as potent as the classical androgens T and dihydrotestosterone (DHT) in activating the androgen receptor and its target genes, updating our understanding of androgen signaling. Therefore, quantification of these multiple androgens may expand our understanding of the hyperandrogenic profile of women with PCOS. This study incorporates traditional androgens and a new series of 11-oxygen and androgen indicators into a model to predict PCOM, a phenotype of PCOS. This model is then combined with other commonly used clinical indicators related to PCOS to explore the causes of PCOM and establish a PCOM prediction model to facilitate the diagnosis of PCOS subtypes.
[0006] Summary of the Invention
[0007] The inventors of the present application have developed a sensitive and accurate mass spectrometry (MS)-based detection method for the simultaneous detection of classical and 11oxyC19androgens. Herein, the inventors have established a method and system for predicting polycystic ovary changes to more accurately predict polycystic ovary changes (PCOM).
[0008] Specifically, this application involves the following:
[0009] 1. A system for predicting polycystic ovary (PCOM), comprising:
[0010] a data acquisition module for acquiring data on the testosterone (T) level, 11-ketoandrostenedione (11KA4) level, androstenedione (A4) level, and 17OH-progesterone (17OHP) level of the subject; and
[0011] The module for calculating the probability of having polycystic ovary (PCOM) is used to calculate the above data information obtained in the data acquisition module, so as to calculate the probability (p) that the subject has polycystic ovary.
[0012] 2. The system according to claim 1, further comprising:
[0013] A grouping module, in which a default grouping parameter for polycystic ovary (PCOM) is pre-stored, and based on the grouping parameter, the calculated probability (p) of polycystic ovary (PCOM) is grouped, thereby grouping the risk of subjects having polycystic ovary.
[0014] 3. A system according to item 1 or 2, wherein the subject is a patient with polycystic ovary syndrome.
[0015] 4. A system according to item 1 or 2, wherein
[0016] The testosterone (T) level refers to the testosterone concentration of the subject detected on any day during the subject's menstrual cycle.
[0017] The 11-ketoandrostenedione (11KA4) level refers to the 11-ketoandrostenedione concentration of the subject detected on any day during the subject's menstrual cycle.
[0018] The androstenedione (A4) level refers to the androstenedione concentration of the subject detected on any day during the subject's menstrual cycle.
[0019] The 17OH-progesterone (17OHP) level refers to the 17OH-progesterone concentration of the subject detected on any day during the subject's menstrual cycle.
[0020] 5. A system according to item 1 or 2, wherein
[0021] In the module for calculating the probability of having polycystic ovary changes, a formula for calculating the probability (p) of a subject having polycystic ovary changes is pre-stored, which is fitted based on the data of the subjects' testosterone (T) levels, androstenedione (A4) levels, 11-ketoandrostenedione (11KA4) levels and 17OH-progesterone (17OHP) levels in an existing database.
[0022] 6. A system according to item 5, wherein:
[0023] The formula is as follows: p = 1 / (1 + e - (a + b * T + c * A4 + d * 11KA4 + f * 11OHP)) (Formula 1)
[0024] Where p is the calculated probability that the subject has polycystic ovary changes, a, b, c, d, and f are unitless parameters, T is the testosterone level, A4 is the androstenedione level, 11KA4 is the 11-ketoandrostenedione androstenedione level, and 17OHP is the 17OH-progesterone level.
[0025] 7. A system according to item 6, wherein
[0026] a is any value from -0.194322 to 3.1655263;
[0027] b is any value from 0.1138558 to 3.0958606;
[0028] c is selected from any value between -0.109174 and 0.2678637;
[0029] d is any value selected from -1.320305 to -0.163216;
[0030] f is selected from any value between -0.281078 and 0.0827339.
[0031] 8. A system according to item 2, wherein:
[0032] The grouping basis pre-stored in the grouping module is:
[0033] When the calculated probability (p) that a subject has polycystic ovary (PCOM) is < 20%, the risk of the subject having PCOM is low;
[0034] When 20% ≤ the calculated probability that the subject has polycystic ovary changes (PCOM) (p) < 40%, the risk of the subject having polycystic ovary changes (PCOM) is low risk;
[0035] When 40% ≤ the calculated probability (p) that the subject has polycystic ovary changes (PCOM) < 90%, the risk of the subject having polycystic ovary changes (PCOM) is higher risk;
[0036] When the calculated probability (p) that the subject has polycystic ovary (PCOM) is ≥ 90%, the risk of the subject having polycystic ovary (PCOM) is high.
[0037] 9. A system for predicting polycystic ovary (PCOM), comprising:
[0038] a data collection module for acquiring data on the subject's anti-Mullerian hormone (AMH) level, testosterone (T) level, and age; and
[0039] The module for calculating the probability of having polycystic ovary (PCOM) is used to calculate the above data information obtained in the data acquisition module, so as to calculate the probability (p) that the subject has polycystic ovary (PCOM).
[0040] 10. The system of clause 9, further comprising:
[0041] A grouping module, in which default polycystic ovary (PCOM) grouping parameters are pre-stored, and the calculated probability (p) of having polycystic ovary (PCOM) is grouped according to the grouping parameters, thereby grouping the risk of subjects having polycystic ovary (PCOM).
[0042] 11. The system of claim 9 or 10, wherein the subject is a patient with polycystic ovary syndrome.
[0043] 12. A system according to item 9 or 10, wherein
[0044] The anti-Mullerian hormone (AMH) level refers to the AMH concentration of the subject detected on any day during the subject's menstrual cycle.
[0045] The testosterone (T) level refers to the testosterone concentration of a subject measured on any day during the subject's menstrual cycle.
[0046] 13. A system according to item 9 or 10, wherein
[0047] In the module for calculating the probability of having polycystic ovary changes (PCOM), a formula for calculating the probability (p) of having polycystic ovary changes is pre-stored, which is fitted based on the data of the subjects' anti-Mullerian hormone (AMH) level, testosterone (T) level and age in the existing database.
[0048] 14. A system according to item 13, wherein
[0049] The formula is the following formula 2: p = 1 / (1 + e - (a + b * AMH + c * T + d * age)) (Formula 2)
[0050] Where p is the calculated probability that the subject has polycystic ovary changes (PCOM), a, b, c, and d are unitless parameters, AMH is the anti-Mullerian hormone (AMH) level, T is the testosterone level, and age is age.
[0051] 15. A system according to item 14, wherein
[0052] a is any value from -2.33502 to 2.6238419;
[0053] b is any value from 0.4500201 to 0.7267895;
[0054] c is selected from any value between -0.349974 and 0.6939225;
[0055] d is selected from any value between -0.132286 and 0.0077054.
[0056] 16. The system of claim 10, wherein:
[0057] The grouping basis pre-stored in the grouping module is:
[0058] When the calculated probability (p) of a subject having polycystic ovary changes (PCOM) is <20%, the risk of a subject having PCOM is low;
[0059] When 20% ≤ the calculated probability that the subject has polycystic ovary changes (PCOM) (p) < 40%, the risk of the subject having polycystic ovary changes (PCOM) is low risk;
[0060] When 40% ≤ the calculated probability (p) that the subject has polycystic ovary changes (PCOM) < 90%, the risk of the subject having polycystic ovary changes (PCOM) is higher risk;
[0061] When the calculated probability (p) that the subject has polycystic ovary (PCOM) is ≥ 90%, the risk of the subject having polycystic ovary (PCOM) is high.
[0062] 17. A method for predicting polycystic ovary (PCOM), comprising:
[0063] a data collection step of obtaining data on the testosterone (T) level, 11-ketoandrostenedione (11KA4) level, androstenedione (A4) level, and 17OH-progesterone (17OHP) level of the subject; and
[0064] The step of calculating the probability of having polycystic ovary (PCOM) is used to calculate the above data information obtained in the data collection step, so as to calculate the probability (p) that the subject has polycystic ovary.
[0065] 18. The method of clause 17, further comprising:
[0066] A grouping step, in which a default grouping parameter for polycystic ovary (PCOM) is pre-stored, and based on the grouping parameter, the calculated probability (p) of polycystic ovary (PCOM) is grouped, thereby grouping the subjects' risk of having polycystic ovary.
[0067] 19. The method of claim 17 or 18, wherein the subject is a patient with polycystic ovary syndrome.
[0068] 20. The method according to item 17 or 18, wherein
[0069] The testosterone (T) level refers to the testosterone concentration of the subject detected on any day during the subject's menstrual cycle.
[0070] The 11-ketoandrostenedione (11KA4) level refers to the 11-ketoandrostenedione concentration of the subject detected on any day during the subject's menstrual cycle.
[0071] The androstenedione (A4) level refers to the androstenedione concentration of the subject detected on any day during the subject's menstrual cycle.
[0072] The 17OH-progesterone (17OHP) level refers to the 17OH-progesterone concentration of the subject detected on any day during the subject's menstrual cycle.
[0073] 21. The method according to item 17 or 18, wherein
[0074] In the step of calculating the probability of having polycystic ovary changes, a formula for calculating the probability (p) of a subject having polycystic ovary changes is pre-stored, which is fitted based on data of the subject's testosterone (T) level, androstenedione (A4) level, 11-ketoandrostenedione (11KA4) level and 17OH-progesterone (17OHP) level in an existing database.
[0075] 22. The method according to claim 21, wherein
[0076] The formula is as follows: p = 1 / (1 + e - (a + b * T + c * A4 + d * 11KA4 + f * 11OHP)) (Formula 1)
[0077] Where p is the calculated probability that the subject has polycystic ovary changes, a, b, c, d, and f are unitless parameters, T is the testosterone level, A4 is the androstenedione level, 11KA4 is the 11-ketoandrostenedione androstenedione level, and 17OHP is the 17OH-progesterone level.
[0078] 23. The method according to claim 22, wherein
[0079] a is any value from -0.194322 to 3.1655263;
[0080] b is any value from 0.1138558 to 3.0958606;
[0081] c is selected from any value between -0.109174 and 0.2678637;
[0082] d is any value selected from -1.320305 to -0.163216;
[0083] f is selected from any value between -0.281078 and 0.0827339.
[0084] 24. The method according to claim 18, wherein
[0085] The grouping basis pre-stored in the grouping step is:
[0086] When the calculated probability (p) of a subject having polycystic ovary changes (PCOM) is <20%, the risk of a subject having PCOM is low;
[0087] When 20% ≤ the calculated probability that the subject has polycystic ovary changes (PCOM) (p) < 40%, the risk of the subject having polycystic ovary changes (PCOM) is low risk;
[0088] When 40% ≤ the calculated probability (p) that the subject has polycystic ovary changes (PCOM) < 90%, the risk of the subject having polycystic ovary changes (PCOM) is higher risk;
[0089] When the calculated probability (p) that the subject has polycystic ovary (PCOM) is ≥ 90%, the risk of the subject having polycystic ovary (PCOM) is high.
[0090] 25. A method for predicting polycystic ovary (PCOM), comprising:
[0091] a data collection step of obtaining data on the subject's anti-Mullerian hormone (AMH) level, testosterone (T) level, and age; and
[0092] The step of calculating the probability of having polycystic ovary (PCOM) calculates the above data information obtained in the data collection step to calculate the probability (p) that the subject has polycystic ovary (PCOM).
[0093] 26. The method of clause 25, further comprising:
[0094] A grouping step, in which default polycystic ovary (PCOM) grouping parameters are pre-stored, and the calculated probability (p) of having polycystic ovary (PCOM) is grouped according to the grouping parameters, thereby grouping the subjects' risk of having polycystic ovary (PCOM).
[0095] 27. The method of claim 25 or 26, wherein the subject is a patient with polycystic ovary syndrome.
[0096] 28. The method according to item 25 or 26, wherein
[0097] The anti-Mullerian hormone (AMH) level refers to the AMH concentration of the subject detected on any day during the subject's menstrual cycle.
[0098] The testosterone (T) level refers to the testosterone concentration of a subject measured on any day during the subject's menstrual cycle.
[0099] 29. The method according to item 25 or 26, wherein
[0100] In the step of calculating the probability of having polycystic ovary changes (PCOM), a formula for calculating the probability (p) of having polycystic ovary changes is pre-stored, which is fitted based on the data of the subjects' anti-Mullerian hormone (AMH) level, testosterone (T) level and age in an existing database.
[0101] 30. The method according to claim 29, wherein
[0102] The formula is the following formula 2: p = 1 / (1 + e - (a + b * AMH + c * T + d * age)) (Formula 2)
[0103] Where p is the calculated probability that the subject has polycystic ovary changes (PCOM), a, b, c, and d are unitless parameters, AMH is the anti-Mullerian hormone (AMH) level, T is the testosterone level, and age is age.
[0104] 31. The method of claim 30, wherein:
[0105] a is any value from -2.33502 to 2.6238419;
[0106] b is any value from 0.4500201 to 0.7267895;
[0107] c is selected from any value between -0.349974 and 0.6939225;
[0108] d is selected from any value between -0.132286 and 0.0077054.
[0109] 32. The method of claim 26, wherein:
[0110] The grouping basis pre-stored in the grouping step is:
[0111] When the calculated probability (p) of a subject having polycystic ovary changes (PCOM) is <20%, the risk of a subject having PCOM is low;
[0112] When 20% ≤ the calculated probability that the subject has polycystic ovary changes (PCOM) (p) < 40%, the risk of the subject having polycystic ovary changes (PCOM) is low risk;
[0113] When 40% ≤ the calculated probability (p) that the subject has polycystic ovary changes (PCOM) < 90%, the risk of the subject having polycystic ovary changes (PCOM) is higher risk;
[0114] When the calculated probability (p) that the subject has polycystic ovary (PCOM) is ≥ 90%, the risk of the subject having polycystic ovary (PCOM) is high.
[0115] Effects of the Invention
[0116] This application establishes two mathematical models for predicting polycystic ovarian changes (PCOM) in patients with polycystic ovary syndrome, namely, considering T level, 11KA4 level, A4 level and 17OHP level, or considering AMH level, T level and age to predict polycystic ovarian changes in patients with polycystic ovary syndrome.
[0117] Polycystic ovary syndrome (PCOS) derives its name from the presence of polycystic ovarian changes (PCOM) on ultrasound in women with menstrual irregularities and hyperandrogenism. However, the 1990 National Institutes of Health (NIH) diagnostic criteria for PCOS did not include PCOM on ultrasound. A recent PCOS consensus workshop sponsored by the European Society of Human Reproduction and Embryology (ESHRE) / American Society for Reproductive Medicine (ASRM) in Rotterdam reemphasized the importance of PCOM in the diagnostic criteria. However, the inclusion of PCOM in the definition of PCOS remains controversial. Indeed, while PCOM is more common in women with PCOS who have oligomenorrhea and hyperandrogenism, it is also found in 16–25% of normal women. Several findings suggest that ovulatory women with PCOM may be at the mildest end of the PCOS phenotypic spectrum.
[0118] In summary, polycystic ovarian changes (PCOM) are one of the diagnostic indicators of PCOS. However, the etiology of PCOM remains unclear. Predicting PCOM not only helps us understand its etiology, but also facilitates the diagnosis of PCOS and helps determine the severity of the PCOS phenotype spectrum. This addresses the current lack of models for analyzing and predicting polycystic ovarian changes (PCOM). BRIEF DESCRIPTION OF THE DRAWINGS
[0119] Figure 1 shows the ROC curve for Model 1;
[0120] Figure 2 shows the ROC curve for Model 2. DETAILED DESCRIPTION
[0121] Anti-Müllerian hormone (AMH) is a hormone secreted by the granulosa cells of the ovarian follicles. Female babies begin producing AMH at 36 weeks of gestation. The more follicles there are in the ovaries, the higher the AMH concentration. Conversely, as follicles are gradually consumed with age and various factors, AMH concentrations also decrease, approaching zero as menopause approaches.
[0122] Testosterone (T) is a typical male hormone secreted by the testicles of men and the ovaries of women. The adrenal glands also secrete a small amount of testosterone. It has the functions of maintaining muscle strength and mass, maintaining bone density and strength, refreshing the mind and improving physical fitness.
[0123] Continuous variables: In statistics, variables are categorized as continuous or categorical, depending on whether their values are continuous. A continuous variable is one that can take on any value within a certain interval. Its value is continuous, and two adjacent values can be divided infinitely, resulting in an infinite number of values. For example, the specifications and dimensions of production parts, or the height, weight, and chest circumference of human measurements are continuous variables, whose values can only be obtained through measurement or quantification. Conversely, discrete variables are those whose values can only be calculated using natural numbers or integer units. For example, the number of enterprises, the number of employees, and the number of equipment can only be counted using the number of units of measurement, and the values of such variables are generally obtained using counting methods.
[0124] Categorical variables refer to variables related to geographic location, demographics, and other factors, and their function is to group survey respondents. Descriptive variables describe the differences between one customer group and others. Most categorical variables are also descriptive variables. Categorical variables can be divided into two categories: unordered categorical variables and ordered categorical variables. Unordered categorical variables are those in which there is no degree or order difference between the categories or attributes. They can be further divided into: 1. Binary categories, such as gender (male vs. female) and drug response (negative vs. positive); 2. Multinomial categories, such as blood type (O, A, B, AB) and occupation (industry, agriculture, commerce, education, military). Ordinal categorical variables, on the other hand, have degree differences between categories. For example, urine glucose test results are categorized as -, ±, +, ++, and +++; and efficacy is categorized as cured, markedly effective, improved, and ineffective. For ordinal categorical variables, the groups should be grouped according to rank order, the number of observations in each group should be counted, and a frequency table of the ordinal variable (each rank) should be compiled. The resulting data is called ordinal data.
[0125] Variable types are not fixed; they can be transformed based on the research objectives. For example, hemoglobin level (g / L) is a numerical variable. If it is categorized into two categories: normal and low hemoglobin, it can be analyzed as binary categorical data. If it is categorized into five levels: severe anemia, moderate anemia, mild anemia, normal, and elevated hemoglobin, it can be analyzed as ordinal data. Sometimes, categorical data can be quantified. For example, if a patient's nausea reaction is represented by 0, 1, 2, and 3, it can be analyzed as a numerical variable (quantitative data).
[0126] Logistic regression is a generalized linear regression analysis model commonly used in fields such as data mining, automated disease diagnosis, and economic forecasting. For example, it can be used to explore risk factors for a disease and predict the probability of disease development based on these factors. For example, in the case of gastric cancer, two groups of people are selected: one with gastric cancer and one without. These groups must have different physical characteristics and lifestyles. Therefore, the dependent variable is whether or not a person has gastric cancer, with a value of "yes" or "no." The independent variables can include a wide range of factors, such as age, gender, dietary habits, and Helicobacter pylori infection. Independent variables can be either continuous or categorical. Logistic regression analysis then derives weights for the independent variables, providing a rough understanding of which factors are risk factors for gastric cancer. Furthermore, these weights can be used to predict a person's likelihood of developing cancer based on the risk factors. The dependent variable in a logistic regression can be either binary or multi-categorical.
[0127] The data fitting model used in this article is a logistic regression model that penalizes the absolute size of the regression model's coefficients based on the value of lambda. A larger penalty pushes the estimates of weaker factors closer to zero, so only the strongest predictors remain in the model.
[0128] Least Absolute Shrinkage and Selection Operator Regression (often simply referred to as Lasso regression) is a compression estimation method based on reducing the set of variables (order reduction). It constructs a penalty function that compresses the coefficients of variables and reduces some regression coefficients to zero, thereby achieving variable selection. It is an algorithm that uses penalty functions to improve the predictive power of models. Using the 1-norm constraint, this algorithm not only addresses high dimensionality and collinearity issues but also imparts sparsity to the established model, effectively enabling the algorithm to automatically select wavelengths during modeling.
[0129] Five-fold cross-validation, also known as five-fold cross-validation, is a commonly used testing method for algorithm accuracy. During validation, the dataset is divided into five parts, with four of the parts used as training data and one as testing data. Each trial produces a corresponding accuracy rate (or error rate). The average of the five accuracy rates (or error rates) is used as an estimate of the algorithm's accuracy. Typically, multiple five-fold cross-validations are performed (for example, five 5-fold cross-validations), and the average of these results is used to estimate the algorithm's accuracy.
[0130] The receiver operating characteristic (ROC) curve, also known as the sensitivity curve, gets its name because each point on the curve reflects the same sensitivity—they all respond to the same stimulus, but the results are obtained under different judgment criteria. The ROC curve is a graph with the false alarm probability on the horizontal axis and the hit probability on the vertical axis, plotting the different results obtained by subjects using different judgment criteria under specific stimulus conditions.
[0131] In this application, polycystic ovary refers to the sum of the number of left and right antral follicles > 24. The antral follicle count is performed between days 2 and 5 of the menstrual cycle by ultrasound scanning each ovary and counting the number of follicles with a diameter between 2 and 10 mm.
[0132] The present application provides a system for predicting polycystic ovary changes, comprising:
[0133] a data acquisition module for acquiring data on the testosterone (T) level, 11-ketoandrostenedione (11KA4) level, androstenedione (A4) level, and 17OH-progesterone (17OHP) level of the subject; and
[0134] The module for calculating the probability of polycystic ovary changes is used to calculate the above-mentioned data information obtained in the data acquisition module, so as to calculate the probability (p) that the subject has polycystic ovary changes. In the module for calculating the probability of polycystic ovary changes, the data of the subject's testosterone (T) level, 11-keto-androstenedione (11KA4) level, androstenedione (A4) level and 17OH-progesterone (17OHP) level are used to calculate the probability (p) that the subject has polycystic ovary changes. Specifically, in the module for calculating the probability of polycystic ovary changes, the subject's testosterone (T) level, 11-keto-androstenedione (11KA4) level, androstenedione (A4) level and 17OH-progesterone (17OHP) level are used as continuous variables.
[0135] Wherein, the testosterone (T) level refers to the testosterone concentration of the experimenter detected on any day in the experimenter's menstrual cycle. The 11-ketoandrostenedione (11KA4) level refers to the 11-ketoandrostenedione concentration of the experimenter detected on any day in the experimenter's menstrual cycle. The androstenedione (A4) level refers to the androstenedione concentration of the experimenter detected on any day in the experimenter's menstrual cycle. The 17OH-progesterone (17OHP) level refers to the 17OH-progesterone concentration of the experimenter detected on any day in the experimenter's menstrual cycle. Testosterone concentration, 11-ketoandrostenedione concentration, androstenedione concentration, 17OH-progesterone concentration can be detected using any method known in the art, such as chromatography, chemical analysis. For example, the detection method of liquid chromatography coupled with tandem mass spectrometry can also be used to detect, and specific detection steps can refer to the method described in CN115541776A.
[0136] In the module for calculating the probability of polycystic ovary syndrome, a formula for calculating the probability of polycystic ovary syndrome (p) is pre-stored based on data from an existing database of testosterone (T) levels, 11-ketoandrostenedione (11KA4) levels, androstenedione (A4) levels, and 17OH-progesterone (17OHP) levels. The probability of polycystic ovary syndrome (p) among subjects is then grouped according to the grouping criteria.
[0137] In this application, the existing database refers to a database consisting of subjects who are currently receiving treatment or have previously received treatment and meet the following inclusion and exclusion criteria. There is no agreement on the sample size of the database. Of course, the larger the sample size of the database, the better. For example, it can be 100 subjects, 200 subjects, 300 subjects, preferably more than 400 subjects, and more preferably more than 500 subjects.
[0138] The module for calculating the probability of polycystic ovary changes uses the following formula (1) to calculate the probability (p) of the subject having polycystic ovary changes: p = 1 / (1+e-(a+b*T+c*A4+d*11KA4+f*11OHP)) (Formula 1)
[0139] Where p is the calculated probability that the subject has polycystic ovary changes, a, b, c, d, and f are unitless parameters, T is the testosterone level, A4 is the androstenedione level, 11KA4 is the 11-ketoandrostenedione androstenedione level, and 17OHP is the 17OH-progesterone level.
[0140] In the module for calculating the probability of polycystic ovary changes, the subject's testosterone (T) level, 11-ketoandrostenedione (11KA4) level, androstenedione (A4) level, and 17OH-progesterone (17OHP) level, as well as the values of a, b, c, d, and f, are entered into the formula for direct calculation.
[0141] Furthermore, a is selected from any value between -0.194322 and 3.1655263, preferably 1.4856023; b is selected from any value between 0.1138558 and 3.0958606, preferably 1.6048582; c is selected from any value between -0.109174 and 0.2678637, preferably 0.0793451; d is selected from any value between -1.320305 and -0.163216, preferably -0.741761.
[0142] Default ovarian polycystic changes grouping parameters are pre-stored in the grouping module of the present application, and the grouping basis pre-stored in the grouping module is: when the calculated probability (p) that the subject has ovarian polycystic changes (PCOM) is <20%, the subject's risk of having ovarian polycystic changes is low risk; when 20%≤the calculated probability (p) that the subject has ovarian polycystic changes (PCOM)<40%, the subject's risk of having ovarian polycystic changes (PCOM) is relatively low risk; when 40%≤the calculated probability (p) that the subject has ovarian polycystic changes (PCOM)<90%, the subject's risk of having ovarian polycystic changes (PCOM) is relatively high risk; when the calculated probability (p) that the subject has ovarian polycystic changes (PCOM) is ≥90%, the subject's risk of having ovarian polycystic changes (PCOM) is high risk.
[0143] In another specific embodiment of the present application, the present application also relates to a method for predicting polycystic ovarian changes in patients with polycystic ovary syndrome, which includes: a data collection step, which obtains data on the subject's testosterone (T) level, 11-ketoandrostenedione (11KA4) level, androstenedione (A4) level and 17OH-progesterone (17OHP) level; and a step of calculating the probability of having polycystic ovarian changes, which calculates the above data information obtained in the data collection step to calculate the probability (p) of the subject having polycystic ovarian changes.
[0144] As described above, the specific contents of the steps performed in the method of the present application, the acquisition, grouping and processing of data on the testosterone (T) level, 11-ketoandrostenedione (11KA4) level, androstenedione (A4) level and 17OH-progesterone (17OHP) level of the subject can all refer to the steps performed by the various modules of the system involved in the above-mentioned present application.
[0145] The present application also provides another system for predicting ovarian polycystic changes, which comprises:
[0146] a data collection module for acquiring data on the subject's anti-Mullerian hormone (AMH) level, testosterone (T) level, and age; and
[0147] The module for calculating the probability of polycystic ovary changes is used to calculate the above-mentioned data information obtained in the data acquisition module, so as to calculate the probability (p) that the subject has polycystic ovary changes. In the module for calculating the probability of polycystic ovary changes, the data of the subject's anti-Mullerian hormone (AMH) level, testosterone (T) level and age are used to calculate the probability (p) that the subject has polycystic ovary changes. Specifically, in the module for calculating the probability of polycystic ovary changes, the subject's anti-Mullerian hormone (AMH) level, testosterone (T) level and age are used as continuous variables.
[0148] Wherein, described anti-Mullerian hormone (AMH) level refers to the anti-Mullerian hormone concentration in the venous blood of female experimenter's menstrual cycle any day.Such as experimenter's menstrual cycle is 28 days, then described anti-Mullerian hormone (AMH) level can be the anti-Mullerian hormone concentration in the venous blood of menstrual cycle day 1, can be the anti-Mullerian hormone concentration in the venous blood of menstrual cycle day 10, can also be the anti-Mullerian hormone concentration in the venous blood of menstrual cycle day 28.Described testosterone (T) level refers to the testosterone concentration of experimenter detected any day in experimenter's menstrual cycle.In the module with ovarian polycystic change probability, the formula for calculating the probability (p) of ovarian polycystic change formed by data fitting based on experimenter's anti-Mullerian hormone (AMH) level, testosterone (T) level and age in existing database is stored in advance.And according to grouping criteria, experimenter has the probability (p) of ovarian polycystic change and is grouped.
[0149] In this application, the existing database refers to a database consisting of subjects who are currently receiving treatment or have previously received treatment and meet the following inclusion and exclusion criteria. There is no agreement on the sample size of the database. Of course, the larger the sample size of the database, the better. For example, it can be 100 subjects, 200 subjects, 300 subjects, preferably more than 400 subjects, and more preferably more than 500 subjects.
[0150] The module for calculating the probability of polycystic ovary changes uses the following formula (2) to calculate the probability (p) of the subject having polycystic ovary changes: p = 1 / (1+e-(a+b*AMH+c*T+d*age)) (Formula 2)
[0151] Where p is the calculated probability that the subject has polycystic ovary changes, a, b, c, and d are unitless parameters, AMH is the anti-Mullerian hormone (AMH) level, T is the testosterone level, and age is age.
[0152] In the module for calculating the probability of polycystic ovary changes, the subject's anti-Mullerian hormone (AMH) level, testosterone (T) level and age, as well as the values of a, b, c, and d can be directly calculated by entering them into Formula 2.
[0153] Furthermore, a is selected from any value between -2.33502 and 2.6238419, preferably 0.1444109;
[0154] b is selected from any value between 0.4500201 and 0.7267895, preferably 0.5884048;
[0155] c is selected from any value between -0.349974 and 0.6939225, preferably 0.1719744;
[0156] d is selected from any value within the range of -0.132286 to 0.0077054, and is preferably -0.06229.
[0157] Default ovarian polycystic changes grouping parameters are pre-stored in the grouping module of the present application, and the grouping basis pre-stored in the grouping module is: when the calculated probability (p) that the subject has ovarian polycystic changes (PCOM) is <20%, the subject's risk of having ovarian polycystic changes is low risk; when 20%≤the calculated probability (p) that the subject has ovarian polycystic changes (PCOM)<40%, the subject's risk of having ovarian polycystic changes (PCOM) is relatively low risk; when 40%≤the calculated probability (p) that the subject has ovarian polycystic changes (PCOM)<90%, the subject's risk of having ovarian polycystic changes (PCOM) is relatively high risk; when the calculated probability (p) that the subject has ovarian polycystic changes (PCOM) is ≥90%, the subject's risk of having ovarian polycystic changes (PCOM) is high risk.
[0158] In another specific embodiment of the present application, the present application also relates to a method for predicting polycystic ovarian changes in patients with polycystic ovary syndrome, which includes: a data collection step, which obtains data on the subject's anti-Mullerian hormone (AMH) level, testosterone (T) level and age; and a step of calculating the probability of having polycystic ovarian changes, which calculates the above data information obtained in the data collection step to calculate the probability (p) of the subject having polycystic ovarian changes.
[0159] As described above, the specific contents of the steps performed in the method of the present application, the acquisition, grouping and processing of the data of the subject's anti-Mullerian hormone (AMH) level, testosterone (T) level and age can all refer to the steps performed by the various modules of the system involved in the above-mentioned present application.
[0160] The system of the present application establishes two mathematical models for predicting polycystic ovarian changes (PCOM) in patients with polycystic ovary syndrome, namely, considering T level, 11KA4 level, A4 level and 17OHP level, or considering AMH level, T level and age to predict polycystic ovarian changes in patients with polycystic ovary syndrome. Among them, testosterone (T) level, 11-keto androsterone androstenedione (11KA4) level, androstenedione (A4) level and 17OH-progesterone (17OHP) level are mainly detected by mass spectrometry. If there is a ready-made clinical mass spectrometry experimental equipment, mass spectrometry data on testosterone (T) level, 11-keto androsterone androstenedione (11KA4) level, androstenedione (A4) level and 17OH-progesterone (17OHP) level can be obtained, but if the AMH index is not tested, the model established with T level, 11KA4 level, A4 level and 17OHP level can be used. If AMH testing is convenient and testosterone testing is routinely available, a more accurate model based on AMH levels, T levels, and age can be used to predict PCOM.
[0161] Example
[0162] Selection of experimental data
[0163] In this example, data from infertile women seeking assisted reproductive technology (ART) treatment at Peking University Third Hospital were used. Patients diagnosed with PCOS and / or commonly associated metabolic disorders, namely obesity and insulin resistance, were included. A total of 462 women aged 20-44 years (30.1 ± 4.0 years) were included. After excluding patients with AFC or no menstrual cycle records, 458 women were included in the analysis of polycystic ovary changes (PCOM).
[0164] All participants underwent a routine oral glucose tolerance test (OGTT). AFC was measured using two-dimensional ultrasound (Hitachi Aloka, Tokyo, Japan). Follicles between 2 mm and 10 mm were considered antral follicles. All participants provided written informed consent. Approval was obtained from the Medical Ethics Committee of Peking University Third Hospital (2019-014-02).
[0165] Serum steroid analysis
[0166] Classical androgens and their precursors, including T, A4, dehydroepiandrosterone (DHEA), and 17OH-progesterone (17OHP), as well as four 11oxyC19 androgens (11OHA4, 11OHT, 11KA4, and 11KT), were determined and quantified using sensitive high-performance liquid chromatography-differential tandem mass spectrometry (HPLC-DMS / MS / MS) instrumentation. The method consisted of a 20A HPLC system (Shimadzu, Chiyoda-ku, Tokyo, Japan) and a 5500QTrap mass spectrometer (AB SCIEX, Framingham, MA, USA), with a SelexIon as the in-house DMS component.
[0167] Serum samples were prepared using dispersive magnetic solid-phase extraction (DMSPE) using magnetic graphene oxide core-shell nanoparticles (Fe3O4@GO) as an adsorbent. Isotopic internal standards were added to the samples before extraction to reduce extraction-induced errors. Following DMSPE, androgen levels were derivatized with Girard's Reagent P to enhance sensitivity.
[0168] Chromatographic separation was performed on an Agilent Poroshell EC C18 column. A gradient mobile phase consisting of methanol and ammonium formate buffer, both containing formic acid, was used. To further distinguish isomers and reduce background noise, a dimethylsulfoxide (DMS) was introduced, and parameters were optimized for each androgen. Tandem mass spectrometry (MS / MS) detection was performed using an electrospray source in positive ionization mode, and multiple reaction monitoring (MRM) conditions were optimized for each compound.
[0169] Biochemical analysis
[0170] Plasma glucose was measured using the glucose oxidase-phenol aminophenol method (Merit Choice Bioengineering, Beijing, China). Insulin was measured using a chemiluminescence assay (Beckman DxI800, Brea, CA, USA). The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated using the following formula: fasting glucose (mmol / L) × fasting insulin (mU / L) / 22.5.
[0171] Statistical analysis
[0172] The outcome variable was PCOM. Polycystic ovary was defined as a number of 24 or more anterior follicles in both ovaries. Normally distributed variables were presented as mean and standard deviation, while non-normally distributed variables were presented as median and interquartile range. Continuous variables were analyzed using independent sample t-tests or nonparametric tests. Least absolute shrinkage and selection operator (LASSO) logistic regression with five-fold cross validation was used to construct the prediction model. The area under the receiver operating characteristic curve (AUC) was used to evaluate the performance of the model. All analyses in this example were performed using SAS JMP Pro (version 14.2; SAS Institute, Cary, NC, USA), and P < 0.05 was considered statistically significant.
[0173] Clinical characteristics of patients
[0174] For the PCOM analysis, a total of 336 patients (336 / 458, 73.4%) were diagnosed with PCOM. Univariate analysis of clinical characteristics of patients with and without PCOM is shown in Table 1. Patients with PCOM were slightly younger than those without PCOM (29.5±3.6 years vs 31.7±4.5 years in the PCOM and non-PCOM groups, respectively, P<0.001). There were no statistically significant differences in body mass index (BMI) and HOMA-IR between the two groups (P>0.05). Anti-Müllerian hormone (AMH), inhibin B, and four androgens in the classical pathway (T, A4, DHEA, and 17OHP) were statistically different between the PCOM and non-PCOM groups (P<0.05).
[0175] Variable selection
[0176] The clinical characteristics of patients with or without ovarian polycystic changes collected in the Examples are shown in Table 1.
[0177] Table 1 Clinical characteristics of patients with or without polycystic ovarian changes
[0178] In Table 1, BMI denotes body mass index; AMH denotes anti-Mullerian hormone; SHBG denotes sex hormone-binding globulin; HOMA-IR denotes homeostatic model assessment of insulin resistance; T denotes testosterone; A4 denotes androstenedione; DHEA denotes dehydroepiandrosterone; 11OHA4 denotes 11β-hydroxyandrostenedione; 11OHT denotes 11β-hydroxytestosterone; 11KA4 denotes 11-ketoenedione; 11KT denotes 11-ketotestosterone; and 17OHP denotes 17OH-progesterone.
[0179] Model construction
[0180] This application constructed two models, Model 1 and Model 2.
[0181] In the construction of Model 1, the subjects' T levels, 11KA4 levels, A4 levels, and 17OHP levels were used as variables.
[0182] First, the data from the 458 subjects used for PCOM analysis were divided into training and validation sets at an 80%:20% ratio. In the training set, least absolute shrinkage and selection operator (LASSO) logistic regression with five-fold cross-validation was used to determine the optimal model. The raw data for the probability of a subject having PCOM and its corresponding predicted values were calculated. Table 2 shows the contribution of each variable in the first model. The main effect refers to the contribution of a single variable to the model, while the total effect is the sum of the contributions of the variable itself and its interaction with other variables. Table 2 shows that the most important contributor was T, with a weight of 51.6%. Other contributors were 11KA4, A4, and 17OHP, with weights of 21.5%, 5.5%, and 3.1%, respectively. Figure 1 shows that the area under the curve (AUC) for this model was 0.835 (95% confidence interval [CI] 0.797–0.873) in the training set and 0.824 (95% CI 0.746–0.902) in the validation set.
[0183] Table 2
[0184] Based on the confirmed model 1, a formula for calculating the probability (p) of a subject having PCOM can be obtained, namely Formula 1, which can calculate the probability (p) of a subject having PCOM based on the data of the subject's T level, 11KA4 level, A4 level and 17OHP level.
[0185] Formula 1: p = 1 / (1 + e - (a + b * T + c * A4 + d * 11KA4 + f * 11OHP))
[0186] Wherein, p is the calculated probability that the subject has polycystic ovary changes, a is 1.4856023, b is 1.6048582, c is 0.0793451, d is -0.741761, and f is -0.099172, T is the testosterone level, A4 is the androstenedione level, 11KA4 is the 11-ketoandrostenedione androstenedione level, and 17OHP is the 17OH-progesterone level.
[0187] Based on the grouping results of the constructed model in the validation set and combined with clinical experience, the following grouping criteria were obtained:
[0188] When the calculated probability (p) that the subject has polycystic ovary changes (PCOM) is <20%, the risk of the subject having polycystic ovary changes is low risk; when 20%≤the calculated probability (p) that the subject has polycystic ovary changes (PCOM)<40%, the risk of the subject having polycystic ovary changes (PCOM) is lower risk; when 40%≤the calculated probability (p) that the subject has polycystic ovary changes (PCOM)<90%, the risk of the subject having polycystic ovary changes (PCOM) is higher risk; when the calculated probability (p) that the subject has polycystic ovary changes (PCOM) is ≥90%, the risk of the subject having polycystic ovary changes (PCOM) is high risk.
[0189] In Model 2, AMH level, T level, and age were used as variables.
[0190] Data from 458 subjects for PCOM analysis were first divided into training and validation sets at an 80%:20% ratio. In the training set, least absolute shrinkage and selection operator (LASSO) logistic regression with five-fold cross-validation was used to determine the optimal model. The raw data for the probability of a subject having PCOM and its corresponding predicted data were calculated.
[0191] As shown in Figure 2, the AUC of the model slightly increased to 0.869 (95% CI 0.834-0.904) in the training group and 0.850 (95% CI 0.777-0.923) in the validation group.
[0192] Based on the confirmed model 2, a formula for calculating the probability (p) that a subject has PCOM can be obtained, namely Formula 2, which can calculate the probability (p) that a subject has PCOM based on the data of the subject's AMH level, T level and age.
[0193] Formula 2: p = 1 / (1 + e - (a + b * AMH + c * T + d * age))
[0194] Where p is the calculated probability that the subject has polycystic ovary changes, a is 0.1444109, b is 0.5884048, c is 0.1719744, d is -0.06229, AMH is the anti-Mullerian hormone (AMH) level, T is the testosterone level, and age is age.
[0195] Both Model 1 and Model 2 can effectively predict the probability of polycystic ovary syndrome in subjects. In Model 1, testosterone (T), 11-keto-androsterone androstenedione (11KA4), androstenedione (A4), and 17OH-progesterone (17OHP) levels are primarily measured using mass spectrometry. If a laboratory has an existing clinical mass spectrometry laboratory and can obtain mass spectrometry data on testosterone (T), 11-keto-androsterone androstenedione (11KA4), androstenedione (A4), and 17OH-progesterone (17OHP) levels, but does not perform AMH testing, Model 1 can be used. If a laboratory has an AMH test and is able to perform routine testosterone testing (testosterone is initially detected by mass spectrometry, and can also be detected using chemiluminescence methods with comparable accuracy to mass spectrometry), Model 2, which has higher detection accuracy, can be used to predict PCOM.
[0196] Based on the grouping results of the constructed model in the validation set and combined with clinical experience, the following grouping criteria were obtained:
[0197] When the calculated probability (p) that the subject has polycystic ovary changes (PCOM) is <20%, the risk of the subject having polycystic ovary changes is low risk; when 20%≤the calculated probability (p) that the subject has polycystic ovary changes (PCOM)<40%, the risk of the subject having polycystic ovary changes (PCOM) is lower risk; when 40%≤the calculated probability (p) that the subject has polycystic ovary changes (PCOM)<90%, the risk of the subject having polycystic ovary changes (PCOM) is higher risk; when the calculated probability (p) that the subject has polycystic ovary changes (PCOM) is ≥90%, the risk of the subject having polycystic ovary changes (PCOM) is high risk.
[0198] In this application, two potential confounders, obesity and insulin resistance, were considered during participant recruitment. A high prevalence of obesity / overweight and insulin resistance was found in all groups, consistent with the majority of PCOS patients. Furthermore, because high androgen levels are common in patients with these metabolic disorders, this patient population was selected to ensure the sensitivity and accuracy of androgen measurement. Under these circumstances, both models in this application demonstrated good predictive ability for PCOS (AUC > 0.8).
[0199] The above specific embodiments are merely illustrative and instructive, and are not restrictive. A person skilled in the art, guided by this specification and without departing from the scope of protection of the claims of this application, may also make many other forms, all of which fall within the scope of protection of this application.
Claims
1. A system for predicting polycystic ovarian-like changes (PCOM), comprising: A data acquisition module for obtaining data on the testosterone (T) level, 11-ketotestosterone (11KA4) level, androstenedione (A4) level, and 17OH-progesterone (17OHP) level of a subject; and A module for calculating the probability of having polycystic ovarian-like changes (PCOM), which is used to calculate the above data information obtained in the data acquisition module to calculate the probability (p) that the subject has polycystic ovarian-like changes.
2. The system according to claim 1, further comprising: A grouping module in which default grouping parameters for polycystic ovarian-like changes (PCOM) are pre-stored, and based on these grouping parameters, the calculated probability (p) of having polycystic ovarian-like changes (PCOM) is grouped, thereby grouping the risk that the subject has polycystic ovarian-like changes.
3. The system according to claim 1 or 2, wherein The subject is a patient with polycystic ovary syndrome.
4. The system according to claim 1 or 2, wherein, The testosterone (T) level refers to the testosterone concentration of the subject measured on any day of the subject's menstrual cycle, The 11-ketotestosterone (11KA4) level refers to the 11-ketotestosterone concentration of the subject measured on any day of the subject's menstrual cycle, The androstenedione (A4) level refers to the androstenedione concentration of the subject measured on any day of the subject's menstrual cycle, The 17OH-progesterone (17OHP) level refers to the 17OH-progesterone concentration of the subject measured on any day of the subject's menstrual cycle.
5. The system according to claim 1 or 2, wherein, In the module for calculating the probability of having polycystic ovarian-like changes, a formula for calculating the probability (p) that the subject has polycystic ovarian-like changes is pre-stored, which is fitted based on the data of the testosterone (T) level, androstenedione (A4) level, 11-ketotestosterone (11KA4) level, and 17OH-progesterone (17OHP) level of the subjects in the existing database.
6. The system according to claim 5, wherein, The formula is Formula 1 as follows: p = 1 / (1 + e^(-(a + b*T + c*A4 + d*11KA4 + f*11OHP))) (Formula 1) Wherein, p is the calculated probability that the subject has polycystic ovarian-like changes, a, b, c, d, f are dimensionless parameters, T is the testosterone level, A4 is the androstenedione level, 11KA4 is the 11-ketotestosterone level, and 17OHP is the 17OH-progesterone level.
7. The system according to claim 6, wherein, a is selected from any value in the range of -0.194322 to 3.1655263; b is selected from any value in the range of 0.1138558 to 3.0958606; c is selected from any value in the range of -0.109174 to 0.2678637; d is selected from any value in the range of -1.320305 to -0.163216; f is selected from any value in the range of -0.281078 to 0.0827339.
8. The system according to claim 2, wherein the grouping basis pre-stored in the grouping module is: when the calculated probability (p) of the subject having polycystic ovarian-like changes (PCOM) < 20%, the risk of the subject having polycystic ovarian-like changes is low risk; when 20% ≤ the calculated probability (p) of the subject having polycystic ovarian-like changes (PCOM) < 40%, the risk of the subject having polycystic ovarian-like changes (PCOM) is relatively low risk; when 40% ≤ the calculated probability (p) of the subject having polycystic ovarian-like changes (PCOM) < 90%, the risk of the subject having polycystic ovarian-like changes (PCOM) is relatively high risk; when the calculated probability (p) of the subject having polycystic ovarian-like changes (PCOM) ≥ 90%, the risk of the subject having polycystic ovarian-like changes (PCOM) is high risk.
9. A system for predicting polycystic ovarian-like changes (PCOM), comprising: a data acquisition module for obtaining data on the anti-Müllerian hormone (AMH) level, testosterone (T) level, and age of a subject; and a module for calculating the probability of having polycystic ovarian-like changes (PCOM), which is used to calculate the above data information obtained in the data acquisition module, so as to calculate the probability (p) of the subject having polycystic ovarian-like changes (PCOM).
10. The system according to claim 9, further comprising: a grouping module in which default polycystic ovarian-like change (PCOM) grouping parameters are pre-stored, and based on these grouping parameters, the calculated probability (p) of having polycystic ovarian-like changes (PCOM) is grouped, so as to group the risk of the subject having polycystic ovarian-like changes (PCOM).
11. The system according to claim 9 or 10, wherein, The subject is a patient with polycystic ovary syndrome.
12. The system according to claim 9 or 10, wherein the anti-Müllerian hormone (AMH) level refers to the AMH concentration of the subject detected on any day of the subject's menstrual cycle, the testosterone (T) level refers to the testosterone concentration of the subject detected on any day of the subject's menstrual cycle.
13. The system according to claim 9 or 10, wherein in the module for calculating the probability of having polycystic ovarian-like changes (PCOM), a formula for calculating the probability (p) of having polycystic ovarian-like changes, which is fitted based on the data of the anti-Müllerian hormone (AMH) level, testosterone (T) level, and age of the subjects in the existing database, is pre-stored.
14. The system according to claim 13, wherein the formula is formula two as follows: p = 1 / (1 + e-(a + b*AMH + c*T + d*age)) (formula two) wherein, p is the calculated probability of the subject having polycystic ovarian-like changes (PCOM), a, b, c, d are unitless parameters, AMH is the anti-Müllerian hormone (AMH) level, T is the testosterone level, and age is the age.
15. The system according to claim 14, wherein a is selected from any value in -2.33502 to 2.6238419; b is selected from any value in the range of 0.4500201 to 0.7267895; c is selected from any value in the range of -0.349974 to 0.6939225; d is selected from any value in the range of -0.132286 to 0.0077054.
16. The system according to claim 10, wherein The grouping basis pre-stored in the grouping module is: When the calculated probability (p) of the subject having polycystic ovarian-like changes (PCOM) < 20%, the risk of the subject having polycystic ovarian-like changes is low risk; When 20% ≤ the calculated probability (p) of the subject having polycystic ovarian-like changes (PCOM) < 40%, the risk of the subject having polycystic ovarian-like changes (PCOM) is relatively low risk; When 40% ≤ the calculated probability (p) of the subject having polycystic ovarian-like changes (PCOM) < 90%, the risk of the subject having polycystic ovarian-like changes (PCOM) is relatively high risk; When the calculated probability (p) of the subject having polycystic ovarian-like changes (PCOM) ≥ 90%, the risk of the subject having polycystic ovarian-like changes (PCOM) is high risk.
17. A method for predicting polycystic ovarian-like changes (PCOM), comprising: A data collection step of obtaining data on the testosterone (T) level, 11-ketoadrostenedione (11KA4) level, androstenedione (A4) level, and 17OH-progesterone (17OHP) level of the subject; and A step of calculating the probability of having polycystic ovarian-like changes (PCOM), which is used to calculate the above data information obtained in the data collection step, so as to calculate the probability (p) of the subject having polycystic ovarian-like changes.
18. The method according to claim 17, further comprising: A grouping step, in which default grouping parameters for polycystic ovarian-like changes (PCOM) are pre-stored, and according to the grouping parameters, the calculated probability (p) of having polycystic ovarian-like changes (PCOM) is grouped, so as to group the risk of the subject having polycystic ovarian-like changes.
19. The method according to claim 17 or 18, wherein The subject is a patient with polycystic ovary syndrome.
20. The method according to claim 17 or 18, wherein The testosterone (T) level refers to the testosterone concentration of the subject detected on any day of the subject's menstrual cycle, The 11-ketoadrostenedione (11KA4) level refers to the 11-ketoadrostenedione concentration of the subject detected on any day of the subject's menstrual cycle, The androstenedione (A4) level refers to the androstenedione concentration of the subject detected on any day of the subject's menstrual cycle, The 17OH-progesterone (17OHP) level refers to the 17OH-progesterone concentration of the subject detected on any day of the subject's menstrual cycle.
21. The method according to claim 17 or 18, wherein In the step of calculating the probability of polycystic ovary - like changes, there is pre - stored a formula for calculating the probability (p) that a subject has polycystic ovary - like changes, which is fitted based on data of the testosterone (T) level, androstenedione (A4) level, 11 - ketoandrostenedione (11KA4) level, and 17 - hydroxyprogesterone (17OHP) level of subjects in an existing database.
22. The method according to claim 21, wherein, the formula is Formula 1 as follows: p = 1 / (1 + e^(-(a + b*T + c*A4 + d*11KA4 + f*11OHP))) (Formula 1) where p is the calculated probability that a subject has polycystic ovary - like changes, a, b, c, d, f are dimensionless parameters, T is the testosterone level, A4 is the androstenedione level, 11KA4 is the 11 - ketoandrostenedione level, and 17OHP is the 17 - hydroxyprogesterone level.
23. The method according to claim 22, wherein, a is selected from any value in the range of - 0.194322 to 3.1655263; b is selected from any value in the range of 0.1138558 to 3.0958606; c is selected from any value in the range of - 0.109174 to 0.2678637; d is selected from any value in the range of - 1.320305 to - 0.163216; f is selected from any value in the range of - 0.281078 to 0.0827339.
24. The method according to claim 18, wherein, the basis for grouping pre - stored in the grouping step is: When the calculated probability (p) that a subject has polycystic ovary - like changes (PCOM) < 20%, the risk that the subject has polycystic ovary - like changes is low risk; When 20% ≤ the calculated probability (p) that a subject has polycystic ovary - like changes (PCOM) < 40%, the risk that the subject has polycystic ovary - like changes (PCOM) is relatively low risk; When 40% ≤ the calculated probability (p) that a subject has polycystic ovary - like changes (PCOM) < 90%, the risk that the subject has polycystic ovary - like changes (PCOM) is relatively high risk; When the calculated probability (p) that a subject has polycystic ovary - like changes (PCOM) ≥ 90%, the risk that the subject has polycystic ovary - like changes (PCOM) is high risk.
25. A method for predicting polycystic ovary - like changes (PCOM), which includes: a data collection step, which obtains data of the anti - Müllerian hormone (AMH) level, testosterone (T) level, and age of a subject; and a step of calculating the probability of polycystic ovary - like changes (PCOM), which calculates the above - obtained data information in the data collection step to calculate the probability (p) that a subject has polycystic ovary - like changes (PCOM).
26. The method according to claim 25, which further includes: Grouping step, in which default polycystic ovary-like change (PCOM) grouping parameters are pre-stored, and based on these grouping parameters, the calculated probability (p) of having polycystic ovary-like change (PCOM) is grouped, so as to group the risk of the subject having polycystic ovary-like change (PCOM).
27. The method according to claim 25 or 26, wherein The subject is a patient with polycystic ovary syndrome.
28. The method according to claim 25 or 26, wherein The anti-Müllerian hormone (AMH) level refers to the AMH concentration of the subject detected on any day of the subject's menstrual cycle. The testosterone (T) level refers to the testosterone concentration of the subject detected on any day of the subject's menstrual cycle.
29. The method according to claim 25 or 26, wherein In the step of calculating the probability of having polycystic ovary-like change (PCOM), a formula for calculating the probability (p) of having polycystic ovary-like change, which is fitted based on the anti-Müllerian hormone (AMH) level, testosterone (T) level and age of the subjects in the existing database, is pre-stored.
30. The method according to claim 29, wherein The formula is Formula Two as follows: p = 1 / (1 + e^-(a + b*AMH + c*T + d*age)) (Formula Two) Wherein, p is the calculated probability of the subject having polycystic ovary-like change (PCOM), a, b, c, d are unitless parameters, AMH is the anti-Müllerian hormone (AMH) level, T is the testosterone level, and age is the age.
31. The method according to claim 30, wherein a is selected from any value in the range of -2.33502 to 2.6238419; b is selected from any value in the range of 0.4500201 to 0.7267895; c is selected from any value in the range of -0.349974 to 0.6939225; d is selected from any value in the range of -0.132286 to 0.0077054.
32. The method according to claim 26, wherein The grouping basis pre-stored in the grouping step is: When the calculated probability (p) of the subject having polycystic ovary-like change (PCOM) < 20%, the risk of the subject having polycystic ovary-like change is low risk; When 20% ≤ the calculated probability (p) of the subject having polycystic ovary-like change (PCOM) < 40%, the risk of the subject having polycystic ovary-like change (PCOM) is relatively low risk; When 40% ≤ the calculated probability (p) of the subject having polycystic ovary-like change (PCOM) < 90%, the risk of the subject having polycystic ovary-like change (PCOM) is relatively high risk; When the calculated probability (p) of the subject having polycystic ovary-like change (PCOM) ≥ 90%, the risk of the subject having polycystic ovary-like change (PCOM) is high risk.
Citation Information
Patent Citations
System for assessing ovarian reserve function of subject
CN112908475A
System and method for diagnosing polycystic ovarian syndrome
CN113035354A
Method and kit for simultaneously detecting five steroid hormones and application thereof
CN114609297A
Method for extracting multiple steroid hormones in biological fluid sample
CN115236246A
Method for evaluating risk of females suffering from PCOS and related products and application thereof
CN115398238A
